These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018). Piérard D; Stone GG BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017-2021. Wise MG; Karlowsky JA; Hackel MA; Harti MA; Ntshole BME; Njagua EN; Oladele R; Samuel C; Khan S; Wadula J; Lowman W; Lembede BW; Sahm DF J Glob Antimicrob Resist; 2023 Dec; 35():93-100. PubMed ID: 37709139 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019. Karlowsky JA; Kazmierczak KM; Valente MLNF; Luengas EL; Baudrit M; Quintana A; Irani P; Stone GG; Sahm DF Braz J Infect Dis; 2021; 25(6):101647. PubMed ID: 34774471 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018. Kiratisin P; Kazmierczak K; Stone GG J Glob Antimicrob Resist; 2021 Dec; 27():132-141. PubMed ID: 34478880 [TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020. Karlowsky JA; Bouchillon SK; Benaouda A; Soraa N; Zerouali K; Mohamed N; Alami T; Sahm DF J Glob Antimicrob Resist; 2022 Sep; 30():23-30. PubMed ID: 35447385 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020. Karlowsky JA; Lob SH; Siddiqui F; Pavia J; DeRyke CA; Young K; Motyl MR; Sahm DF Braz J Infect Dis; 2023; 27(3):102775. PubMed ID: 37169345 [TBL] [Abstract][Full Text] [Related]
8. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017). Ko WC; Stone GG Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Malaysia: Results from the ATLAS Programme, 2013 to 2019. Tuan Soh TS; Salvinder S; Chen VSY Med J Malaysia; 2022 Mar; 77(2):174-184. PubMed ID: 35338624 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of carbapenemase genes among carbapenem-nonsusceptible Castanheira M; Deshpande LM; Mendes RE; Doyle TB; Sader HS JAC Antimicrob Resist; 2022 Oct; 4(5):dlac098. PubMed ID: 36196444 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020. Karlowsky JA; Lob SH; Chen WT; DeRyke CA; Siddiqui F; Young K; Motyl MR; Sahm DF Int J Antimicrob Agents; 2023 Sep; 62(3):106900. PubMed ID: 37354921 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017. Stone GG; Seifert H; Nord CE Int J Antimicrob Agents; 2020 Sep; 56(3):106045. PubMed ID: 32522673 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftazidime/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017. Stone GG; Ponce-de-Leon A J Antimicrob Chemother; 2020 Jul; 75(7):1859-1873. PubMed ID: 32277820 [TBL] [Abstract][Full Text] [Related]
20. Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17. Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF J Antimicrob Chemother; 2020 May; 75(5):1165-1173. PubMed ID: 32040168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]